Dr. Bess Flashner, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- George Washington University School of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 265
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: George Washington University School of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
MA license 278924 -
Internal Medicine Physician
MA license 264176
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Beth Israel Deaconess Medical Center Boston, MA
- Beth Israel Deaconess Hospital - Needham Needham, MA
- George Washington Univ Hospital Washington, DC
Medical groups
- Medical Faculty Associates, Inc (672 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 265
- Services billed
- 661
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Test to measure expiratory airflow and volume | 199 | 197 |
| Established patient office or other outpatient visit, 40-54 minutes | 173 | 99 |
| Critical care, first 30-74 minutes | 153 | 75 |
| Test to examine how well the lungs exchange gases | 96 | 94 |
| New patient office or other outpatient visit, 60-74 minutes | 51 | 51 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 23 | 23 |
| Test to determine lung volumes using gas dilution or washout | 23 | 23 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 22 | 17 |
| Test to determine lung volumes using sensors | 18 | 18 |
| Critical care, each additional 30 minutes | 15 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Boston, MA | 154 |
| Ofev (nintedanib esylate) | 84 |
| Prednisone Other prescribers in Boston, MA | 64 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Boston, MA | 45 |
| Wixela Inhub (fluticasone propion/salmeterol) Other prescribers in Boston, MA | 45 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Boston, MA | 38 |
| Pirfenidone | 31 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Boston, MA | 30 |
| Mycophenolate Mofetil Other prescribers in Boston, MA | 29 |
| Stiolto Respimat (tiotropium br/olodaterol hcl) Other prescribers in Boston, MA | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $3,778 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,778 |
|---|
| Consulting Fee | $3,690 |
|---|---|
| Travel and Lodging | $88.07 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Jan 7, 2025 | Consulting Fee | $3,690 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jan 7, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $88.07 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $35,142 in research payments for these studies, mostly to the institutions running them.
- An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
Boehringer Ingelheim Pharmaceuticals, Inc. - An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.